Free Trial
→ Trump’s new nightmare begins (From Porter & Company) (Ad)tc pixel

Zhengye Biotechnology (NASDAQ:ZYBT) Trading 5.3% Higher - Still a Buy?

Written by MarketBeat
Updated September 1, 2025
Zhengye Biotechnology logo with Medical background

Key Points

  • Zhengye Biotechnology's share price increased by 5.3% to $8.42 during mid-day trading on Tuesday, despite a significant drop in trading volume.
  • Wall Street analysts have upgraded the stock to a "hold" rating, indicating a cautious optimism about its future performance.
  • Several large investors, including Geode Capital Management and Invesco Ltd., have recently purchased new stakes in Zhengye Biotechnology, signaling potential confidence from institutional investors.
  • Five stocks we like better than Zhengye Biotechnology.

Shares of Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT - Get Free Report) shot up 5.3% during mid-day trading on Tuesday . The stock traded as high as $8.96 and last traded at $8.42. 44,872 shares traded hands during mid-day trading, a decline of 69% from the average session volume of 145,402 shares. The stock had previously closed at $8.00.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Zhengye Biotechnology to a "hold" rating in a report on Saturday, August 2nd.

Get Our Latest Report on Zhengye Biotechnology

Zhengye Biotechnology Stock Up 5.5%

The company has a current ratio of 1.31, a quick ratio of 0.88 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $6.59 and a 200 day moving average of $6.79.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC acquired a new position in shares of Zhengye Biotechnology during the 2nd quarter worth about $174,000. Invesco Ltd. acquired a new position in shares of Zhengye Biotechnology during the 2nd quarter worth about $220,000. Finally, Jane Street Group LLC acquired a new position in shares of Zhengye Biotechnology during the 2nd quarter worth about $1,158,000.

About Zhengye Biotechnology

(Get Free Report)

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

Further Reading

Should You Invest $1,000 in Zhengye Biotechnology Right Now?

Before you consider Zhengye Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zhengye Biotechnology wasn't on the list.

While Zhengye Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover
Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.